Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CD6-H5254 | Human | Human CD46 Protein, Fc Tag (MALS verified) |
|
||
CD6-H5226 | Human | Human CD46 Protein, His Tag (MALS verified) |
|
The purity of Human CD46 Protein, Fc Tag (Cat. No. CD6-H5254) is more than 90% and the molecular weight of this protein is around 85-105 kDa verified by SEC-MALS.
The purity of Human CD46, His Tag (Cat. No. CD6-H5226) is more than 95% and the molecular weight of this protein is around 40-55 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
FOR-46 | FOR-46; FG-3246 | Phase 2 Clinical | University Of California San Diego, Fortis Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Prostatic Neoplasms | Details |
Enadenotucirev | ColoAd-1; Oncolytic Ad11/Ad3 | Phase 1 Clinical | Akamis Bio Ltd | Ovarian Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Neoplasms, Glandular and Epithelial; Urinary Bladder Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
YS-5 | YS-5 | Phase 1 Clinical | Fortis Therapeutics Inc, United States Department Of Defense | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
FOR-46 | FOR-46; FG-3246 | Phase 2 Clinical | University Of California San Diego, Fortis Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Prostatic Neoplasms | Details |
Enadenotucirev | ColoAd-1; Oncolytic Ad11/Ad3 | Phase 1 Clinical | Akamis Bio Ltd | Ovarian Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Neoplasms, Glandular and Epithelial; Urinary Bladder Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
YS-5 | YS-5 | Phase 1 Clinical | Fortis Therapeutics Inc, United States Department Of Defense | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
This web search service is supported by Google Inc.